Relationship between disease activity and patient-reported outcomes in rheumatoid arthritis: Post hoc analyses of overall and Japanese results from two phase 3 clinical trials

References

• Tobon GJ, Youinou P, Saraux A. The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. J Autoimmun. 2010;35:10–14.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Sugiyama N, Inoue E, Taniguchi A, Momohara S. Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I). Mod Rheumatol. 2014;24:33–40.
   PubMed Web of Science ®Google Scholar
• Carr A, Hewlett S, Hughes R, Mitchell H, Ryan S, Carr M, et al. Rheumatology outcomes: the patient’s perspective. J Rheumatol. 2003;30:880–3.
   PubMed Web of Science ®Google Scholar
• Strand V, Cohen S, Crawford B, Smolen JS, Scott DL. Leflunomide Investigators G. Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis. Rheumatology (Oxford). 2004;43:640–7.
   PubMed Web of Science ®Google Scholar
• Pollard L, Choy EH, Scott DL. The consequences of rheumatoid arthritis: quality of life measures in the individual patient. Clin Exp Rheumatol. 2005;23:S43–S52.
   PubMed Web of Science ®Google Scholar
• Klarenbeek NB, Guler-Yuksel M, van der Kooij SM, Han KH, Ronday HK, Kerstens PJ, et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis. 2011;70:1039–46.
   PubMed Web of Science ®Google Scholar
• Sruamsiri R, Mahlich J, Tanaka E, Yamanaka H. Productivity loss of Japanese patients with rheumatoid arthritis - a cross-sectional survey. Mod Rheumatol. 2017. [Epub ahead of print]. doi:10.1080/14397595.2017.1361893
   PubMed Web of Science ®Google Scholar
• Sakai R, Hirano F, Kihara M, Yokoyama W, Yamazaki H, Harada S, et al. High prevalence of cardiovascular comorbidities in patients with rheumatoid arthritis from a population-based cross-sectional study of a Japanese health insurance database. Mod Rheumatol. 2016;26:522–8.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3–15.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis. 2008;67:1360–4.
   PubMed Web of Science ®Google Scholar
• Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res. 2012;64:640–7.
   PubMed Web of Science ®Google Scholar
• Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis. 2016;75:16–22.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int. 2016;36:685–95.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Kitas GD, van Riel PL. Burden of disease in treated rheumatoid arthritis patients: going beyond the joint. Semin Arthritis Rheum. 2014;43:479–88.
   PubMed Web of Science ®Google Scholar
• Gossec L, Dougados M, Dixon W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open. 2015;1:e000019.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labeling claims. 2009. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf [last accessed 28 August 2017].
   Google Scholar
• Fleischmann R, Strand V, Wilkinson B, Kwok K, Bananis E. Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naive patients with rheumatoid arthritis. RMD Open. 2016;2:e000232.
   PubMed Web of Science ®Google Scholar
• Olsen CL, Lie E, Kvien TK, Zangi HA. Predictors of fatigue in rheumatoid arthritis patients in remission or in a low disease activity state. Arthritis Care Res (Hoboken). 2016;68:1043–8.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Shan Y, Harrold L, Zhang J, Greenberg JD, Reed GW. Patient perspectives on achieving treat-to-target goals: a critical examination of patient-reported outcomes. Arthritis Care Res (Hoboken). 2013;65:1707–12.
   PubMed Web of Science ®Google Scholar
• Radner H, Smolen JS, Aletaha D. Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Res Ther. 2014;16:R56.
   PubMed Web of Science ®Google Scholar
• Tang AC, Kim H, Crawford B, Ishii T, Treuer T. The use of patient-reported outcome measures for rheumatoid arthritis in Japan: a systematic literature review. Open Rheumatol J. 2017;11:43–52.
   PubMedGoogle Scholar
• Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376:652–62.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis. Rheumatology. 2017;69:506–17.
   Web of Science ®Google Scholar
• Keystone EC, Taylor PC, Tanaka Y, Gaich C, DeLozier AM, Dudek A, et al. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. Ann Rheum Dis. 2017;76:1853–61.
   PubMed Web of Science ®Google Scholar
• Schiff M, Takeuchi T, Fleischmann R, Gaich CL, DeLozier AM, Schlichting D, et al. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Res Ther. 2017;19:208.
   PubMed Web of Science ®Google Scholar
• Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63:573–86.
   PubMed Web of Science ®Google Scholar
• Kojima M, Kojima T, Suzuki S, Takahashi N, Funahashi K, Asai S, et al. Patient-reported outcomes as assessment tools and predictors of long-term prognosis: a 7-year follow-up study of patients with rheumatoid arthritis. Int J Rheum Dis. 2017;20:1193–1200.
   PubMed Web of Science ®Google Scholar
• Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557–60.
   PubMed Web of Science ®Google Scholar
• Keystone E, Burmester GR, Furie R, Loveless JE, Emery P, Kremer J, et al. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum. 2008;59:785–93.
   PubMed Web of Science ®Google Scholar
• Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs. 2010;70:121–45.
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Ikeda K, Nakamura T, Yamagata M, Nakazawa T, Tanaka S, et al. Severity and diurnal improvement of morning stiffness independently associate with tenosynovitis in patients with rheumatoid arthritis. PLoS One. 2016;11:e0166616.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Takeuchi T, Cai Z, Sato M, Awakura K, Gaich C, et al. Determinants of Patient?s Global Assessment of Disease Activity and Physician?s Global Assessment of Disease Activity in patients with rheumatoid arthritis: A post hoc analysis of overall and Japanese results from phase 3 clinical trials. Mod Rheumatol. 2017. [Epub ahead of print]. doi:10.1080/14397595.2017.1422304
   Web of Science ®Google Scholar
• Matcham F, Scott IC, Rayner L, Hotopf M, Kingsley GH, Norton S, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44:123–30.
   PubMed Web of Science ®Google Scholar
• Fautrel B, van de LM, Kirkham B, Alten R, Cseuz R, Van der Geest S, et al. Differences in patient-reported outcomes between baricitinib and comparators among patients with rheumatoid arthritis who achieved low disease activity or remission. Ann Rheum Dis. 2017;76(Suppl. 2):230.
   Web of Science ®Google Scholar